Discontinued — last reported Q3 '25
Distributions to noncontrolling interests
Royalty Pharma Distributions to noncontrolling interests decreased by 2.1% to $39.88M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 25.9%, from $53.83M to $39.88M. Over 3 years (FY 2022 to FY 2025), Distributions to noncontrolling interests shows an upward trend with a 5.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase reflects higher profitability of the subsidiary or a change in distribution policy, while a decrease may indicate lower subsidiary earnings.
Detailed definition
This represents cash payments made to minority shareholders or partners who hold an interest in a subsidiary that is con...
Peer comparison
Relevant for companies with complex partnership structures or master limited partnership (MLP) components.
distributions_to_noncontrollingHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $112.48M | $125.43M | $34.52M | $37.83M | $38.62M | $33.15M | $33.39M | $30.53M | $31.12M | $24.49M | $32.01M | $30.68M | $31.02M | $31.45M | $53.83M | $38.61M | $34.28M | $40.76M | $39.88M |
| QoQ Change | — | +11.5% | -72.5% | +9.6% | +2.1% | -14.2% | +0.7% | -8.6% | +1.9% | -21.3% | +30.7% | -4.2% | +1.1% | +1.4% | +71.2% | -28.3% | -11.2% | +18.9% | -2.1% |
| YoY Change | — | — | — | -66.4% | -69.2% | — | -3.2% | -19.3% | -19.4% | -26.1% | -4.1% | +0.5% | -0.3% | +28.4% | +68.2% | +25.8% | +10.5% | +29.6% | -25.9% |
Distributions to noncontrolling interests at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's distributions to noncontrolling interests?
- Royalty Pharma (RPRX) reported distributions to noncontrolling interests of $39.88M in Q1 2026.
- How has Royalty Pharma's distributions to noncontrolling interests changed year-over-year?
- Royalty Pharma's distributions to noncontrolling interests decreased by 25.9% year-over-year, from $53.83M to $39.88M.
- What is the long-term trend for Royalty Pharma's distributions to noncontrolling interests?
- Over 3 years (2022 to 2025), Royalty Pharma's distributions to noncontrolling interests has grown at a 5.1% compound annual growth rate (CAGR), from $144.12M to $167.48M.
- What does distributions to noncontrolling interests mean?
- Cash payments made to minority partners or shareholders of consolidated subsidiaries.